Paul Jenkinson served as Chief Financial Officer Kite Pharma, Inc. a leading developer of CAR-T immunotherapies for cancer, until its $12BN sale to Gilead Sciences, Inc. in late 2017. Previously he was Vice President of Global Commercial Finance and Corporate Finance at Allergan, Inc., a global pharmaceutical company. In this role, he was responsible for the corporation’s financial planning and analysis activities, working with commercial operations, manufacturing operations, research and development, and general and administration functions in multiple international markets. His responsibilities also included global commercial finance with a focus on performance and system-wide revenue and cost management initiatives.
Previously, Mr. Jenkinson served in finance positions at Black & Decker Corporation (presently Stanley Black & Decker), attaining the position of Vice President, Corporate Officer, at the Kwikset, Baldwin and Weiser Lock Companies. He began his career in finance positions at Deloitte New Zealand and later at a predecessor company of Fonterra. Mr. Jenkinson holds a Bachelor of Commerce degree in Accounting & Finance and Marketing from the University of Otago, New Zealand, and is an active member of Chartered Accountants Australia and New Zealand.